APLAR 2021– Beyond RA Congress Preview

Enhancing knowledge of the clinical
importance of cytokine signalling
The Cytokine Signalling Forum
www.cytokinesignalling.com
APLAR 2021
Congress Preview
Beyond
Rheumatoid Arthritis
Register for FREE content at www.cytokinesignalling.com
DEVELOPED UNDER
THE AUSPICES OF THE
Follow us at:
Cytokine Signalling Forum

Key Presentations
Saturday 28 th August 2021
13:00 – 15:00 GRAPPA Workshop Part 1
Opening remarks
Philip Mease
Recent topics in diagnosis of PsA
Vinod Chandran
Diagnosis approach challenging to psoriasis skin
Akimichi Morita
Imaging in PsA: Update in 2021
Ashish J Mathew
Comorbidity in PsA: recent topics
Ho So
15:15 – 16:00 GRAPPA Workshop Part 2
Clinical disease activity measures in daily practice
Rieke Alten
GRAPPA 2021 treatment recommendation
Live Q&A
Ying Ying Leung
Closing remarks
Mitsumasa Kishimoto
Sunday 29 th August 2021
10:20– 11:35 Morning Industry Symposium 1: New Insights for Basic and Clinical
Practice in SpA
Brought to you by Novartis
Chairs: Yoshiya Tanaka IP and Hideto Kameda IP
Role of IL-17 in spondyloarthritis: from the standpoint of osteoimmunology
Kojiro Sato V
New insights in Spondyloarthritis from clinical perspectives - Where we are and
where to
Masato Okada IP

10:20– 11:35 Morning Industry Symposium 4: Targeting JAKs in Rheumatology:
Outcomes in Different Disease States
Brought to you by Eli Lilly
Chair: Kevin Winthrop
JAK inhibition in Rheumatoid Arthritis
Rieke Alten
JAK Inhibitors in SpA
Lai-Shan Tam
JAK Inhibitors in SLE
Eric Morand
JAK Inhibitors and COVID-19
Kevin Winthrop
13:15 – 14:55 ABSTRACT SESSION 3
Long-Term Safety and Effectiveness of Upadacitinib in Patients with Psoriatic
Arthritis: Results at 56 weeks from the SELECT-PsA 1 Study
Mitsumasa Kishimoto
Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related
Symptoms of Psoriatic Arthritis: Results from Two Phase-3, Randomized,
Placebo-controlled Studies
Philip Mease
Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as
Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
Philip Mease
Correlations Between Reductions in Fatigue Severity and Improvements in Physical
Function and Clinical Response in PsA Patients: Phase-3 DISCOVER Results
Arthur Kavanaugh
Comparable Safety Profile of Guselkumab in Psoriatic Arthritis and Psoriasis:
Results from Phase 3 Trials Through 1 Year
April Armstrong
Guselkumab Treatment Modulates Core Psoriatic Arthritis Gene Expression in Two
Phase 3 Clinical Trials (DISCOVER-1 and -2)
Peter Nash
Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and
Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial
Christopher Ritchlin

13:15 – 14:55 Axial Spondyloarthritis – From Bench to Bed Side
Chair: Mitsumasa Kishimoto
Axial Spondyloarthritis and Axial Psoriatic Arthritis
Philip Mease
Effect of Secukinumab versus Adalimumab on ACR Core Components and
Health-related Quality of Life in patients with Psoriatic Arthritis: Results from
the EXCEED study
Peter Nash
Cardiovascular Comorbidity in Axial Spondyloarthritis - What is New?
Lai-Shan Tam
Cutting edge advances in axial SpA
Xenofon Baraliakos
15:55 – 17:35 SpA Symposium
Chairs: James Wei, Mitsumasa Kishimoto and Khalid Alnaqbi
Innovation and Progress in AS Research on New Bone Formation
Chin-Hsiu Liu
New Grappa Recommendation - peripheral arthritis focus
Katy Leung
Axial psoriatic arthritis - is it different from axial spondyloarthritis?
Lai-Shan Tam
Monday 30 th August 2021
07:30 – 08:50 ACR - APLAR Invited Session
Chair: Yoshiya Tanaka and Rohini Handa
Known knowns, and known unknowns, about COVID vaccination in rheumatic
disease patients
Jeffrey Curtis
Progress in Psoriatic Arthritis
Philip Mease
Racial differences in systemic sclerosis phenotype and mortality: a focus on Asians
Lorinda Chung
13:15 – 14:55 ABSTRACT SESSION 4
Chairs: Masataka Kuwana and Masaki Shimizu
Efficacy and Safety of Tofacitinib in the Treatment of Refractory cases of
Polyarticular Course Juvenile Idiopathic Arthritis
Mohammad Rahman

08:50 – 10:20 PLENARY SESSION 2
Chair: Tsutomu Takeuchi
Remission for all (?)
Daniel Aletaha
PsA – pathogenesis delivering therapeutics
Iain McInnes
Are there unmet needs in psoriatic arthritis?
Atulya Deodhar
11:35– 13:15 Lunch Industry Symposium 4: Innovative Therapeutic Alternatives for
Rheumatoid Arthritis, and Psoriatic Arthritis: Individualising the
Treatment Approach
Brought to you by Eli Lilly
Chair: Tsutomu Takeuchi
Strategy for the management of Rheumatoid Arthritis: Updated evidence
from Baricitinib
Tatsuya Atsumi
IL17 inhibition becoming an established treatment for Psoriatic Arthritis
Dennis McGonagle
13:15 – 14:55 ABSTRACT SESSION 5
Chair: Hideto Kameda
Responsiveness of Ultrasound Synovitis and Clinical Outcomes in Psoriatic
Arthritis Treated with Secukinumab: Data from the ULTIMATE Trial
Philip Conaghan
Guselkumab Provides Sustained Improvements in Work Productivity and
Non-work Activity in Psoriatic Arthritis Patients: Phase 3 Results Through Year 1
Steve Peterson
Efficacy and Safety of Ixekizumab Vs. Adalimumab (SPIRIT-H2H) With and Without
Concomitant Conventional Synthetic Disease-Modifying Antirheumatic Drugs
(DMARDs) in Biologic DMARD-Naïve Patients with Psoriatic Arthritis: 52-Week Results
Ayako Konomi
Efficacy of Ixekizumab Versus Adalimumab in Psoriatic Arthritis Patients
With/Without Moderate-To-Severe Psoriasis: 52-Week Results from a Multicentre,
Randomised Open-label Study
Masato Okada
Secukinumab provides sustained improvement in Non-radiographic Axial
Spondyloarthritis: 2-year data from the PREVENT study
Hideto Kameda
Persistence on Biologics in of Axial spondyloarthritis Patients – Data from
Moscow Unified Register of Arthritis (MUAR)
Karine Lytkina

Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing
Spondylitis:1Year Results from Randomized, Double-Blind, Placebo-Controlled
Study with Open Label Extension
Mitsumasa Kishimoto
Are NSAIDs In Suspected Axial Spondyloarthropathy Patients Reducing the Yield
Of MRI Imaging?
Prasanna Partha Sarathy
Efficacy and Safety of Secukinumab for Treating Ankylosing Spondylitis in China,
Japan, and Korea: A Systematic Literature Review
Lina Chen
17:35– 18:35 Evening Industry Symposium 5: Transforming Management in PsA:
Integrating Novel Approaches in Clinical Practice
Brought to you by AbbVie
Chair: Tatsuya Atsumi
The import role of JAKs in the Treatment of Psoriatic Arthritis
John Isaacs
The management of Psoriatic Arthritis treatment
Kei Ikeda
Tuesday 31 st August 2021
08:00 – 09:00 ABSTRACT SESSION 6
Japanese COVID-19 registry study among patients with rheumatic diseases
Yasutaka Kimoto
10:45 – 12:25 Image in Rheumatic Diseases - What does the Future Hold?
Chairs: Chi-Chen Chang and Zhuo-Li Zhang
Ultrasound and its clinical use in Crystal induced arthritis
Yohei Seto
Ultrasound and its clinical use in Sjogren syndrome
Helen Keen
Ultrasound and its clinical use in Psoriatic arthritis
Kong Kok Ooi
12:35– 13:45 Lunch Industry Symposium 6: Achieving Remission: Treatment without
Compromise for Women Living with Rheumatic Diseases
Brought to you by UCB Biopharma SRL
Chair: Tsutomu Takeuchi
Disease Control in Women of Childbearing Age with RA: Finding the Right Solution
without Compromise
Megan Clowse
The Holistic Care of Patients with PsA
Mitsumasa Kishimoto

14:45– 16:25 COVID-19 in RMDs: Where are we now? The European Experience
Chairs: Annamaria Iagnocco and Kazuhiko Yamamoto
EULAR COVID-19 database and EULAR COVAX Database
Pedro Machado
Pathogenesis and therapy with rheumatic drugs in COVID
Dennis McGonagle
2019 update of EULAR recommendations for vaccinations in adult patients with
autoiummune inflammatory RMDs
Ori Elkayam
The immune response to COVID-19 vaccinations in patients with impaired
immune systems: the OCTAVE study
Iain McInnes
POSTERS
Features of COVID-19 in patients with immunoinflammatory rheumatological diseases (register data)
Eugenia Aronova
Remote monitoring of patients with axial spondyloarthritis in the COVID-19 pandemic:
the «ASpine» technology
Daria Rumiantceva
Combination therapy of COVID-19 led to an exacerbation of psoriasis and psoriatic arthritis:
a clinical case
Daria Rumiantceva
COVID-19 Vaccine acceptance in patients with rheumatic and musculoskeletal diseases:
A hopeful prospect
Ravinash Ratnam
Intent Of COVID 19 Vaccination in Patients with Rheumatic Diseases
Naga Prabu
Teleconsultations for rheumatic diseases during COVID-19 pandemic: Usefulness, patient response
and prospects for future practice
Ranjan Gupta
Outcomes Of COVID-19 In Patients with Rheumatic Diseases in A Tertiary Government Hospital in
The Philippines
Jamela Lynn Compuesto
COVID-19 in patients with chronic inflammatory rheumatism under biological disease-modifying
antirheumatic drug
Naima Bahaz
Exploring Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis Treatment in
The Middle East and Northern Africa: Observational Phase 4 Study
Adeeba Al-Herz

Case report: An excellent response to Tofacitinib in distal extremity swelling with pitting edema in a
patient with psoriatic arthritis
Jiang Su
Use of Ixekizumab in A Case of Recalcitrant Psoriatic Arthritis
Chuang Tin Quake
Abnormal Liver Function Test in Psoriatic Arthropathy: DMARDs, the Only Culprit?
Chuang Tin Quake
Guselkumab-Treated PsA Patients Achieved Clinically Meaningful Improvements in General Health
Outcomes Measured with PROMIS-29 Through 52 Weeks in DISCOVER-1 Trial
Peter Nash
Guselkumab Treatment Shows Rapid Onset of Effect on Components of ACR Response Criteria:
Results of 2 Randomized Phase 3 Trials
Peter Nash
Survival of Secukinumab for Psoriatic Arthritis patients: a real-world cohort/experience
Codrina Ancuta
Factor associated with drug efficacy, survival and tapering of biologic therapies in Spondyloarthritis
and Rheumatoid arthritis
Darika Songwut
Sustained Guselkumab Response in Patients with Active PsA Regardless of Baseline Demographic/
Disease Characteristics: Results Through Week-52 of Two Phase-3 Studies
May Shawi
Efficacy and Safety of Guselkumab, Anti-Interleukin-23p19-subunit mAb, Through 2-Years: Phase-3,
Randomized, Double-blind, Placebo-controlled Study in Biologic-naïve Patients with Active PsA
Iain McInnes
Secukinumab in Pakistani patients with Ankylosing Spondylitis
Sumera Ghani
Secukinumab in Pakistani patients with Psoriatic Arthritis: Real world experience
Muhammad Ahmed Saeed
Consensus-based recommendations for the management of axial spondyloarthritis patients in the
Kingdom of Saudi Arabia
Hanan Al Rayes
Clinical characteristics of ankylosing spondylitis and quality of life in patients with Ankylosing
spondylitis in Mongolia
Lkham-erdene Byambadoo
Health related quality of life of patients with axial spondyloarthropathy and associated factors at a
tertiary care in Sri Lanka
Suren William De Silva
Anxiety and Depression in Axial Spondyloarthritis Patients: A Pilot Study from Bangladesh
Tania Kabir

SPONSORSHIP AND
UNRESTRICTED EDUCATIONAL
GRANTS FROM
IN PARTNERSHIP
WITH
Register for FREE content at www.cytokinesignalling.com
DEVELOPED UNDER
THE AUSPICES OF THE
Follow us at:
Cytokine Signalling Forum